The Lancet Healthy Longevity,
Journal Year:
2024,
Volume and Issue:
5(6), P. e406 - e421
Published: May 30, 2024
More
than
57
million
people
have
dementia
worldwide.
Evidence
indicates
a
change
in
prevalence
and
incidence
high-income
countries,
which
is
likely
to
be
due
improved
life-course
population
health.
Identifying
key
modifiable
risk
factors
for
essential
informing
reduction
prevention
strategies.
We
therefore
aimed
estimate
the
attributable
fraction
(PAF)
associated
with
factors.
The Lancet Global Health,
Journal Year:
2024,
Volume and Issue:
12(8), P. e1232 - e1243
Published: June 25, 2024
BackgroundInsufficient
physical
activity
increases
the
risk
of
non-communicable
diseases,
poor
and
cognitive
function,
weight
gain,
mental
ill-health.
Global
prevalence
adult
insufficient
was
last
published
for
2016,
with
limited
trend
data.
We
aimed
to
estimate
197
countries
territories,
from
2000
2022.MethodsWe
collated
reported
by
adults
(aged
≥18
years)
in
population-based
surveys.
Insufficient
defined
as
not
doing
150
minutes
moderate-intensity
activity,
75
vigorous-intensity
or
an
equivalent
combination
per
week.
used
a
Bayesian
hierarchical
model
compute
estimates
country
territory,
year,
age,
sex.
assessed
whether
regions,
world
would
meet
global
target
15%
relative
reduction
2030
if
2010–22
trends
continue.FindingsWe
included
507
surveys
across
163
territories.
The
age-standardised
31·3%
(95%
uncertainty
interval
28·6–34·0)
2022,
increase
23·4%
(21·1–26·0)
26·4%
(24·8–27·9)
2010.
Prevalence
increasing
103
(52%)
territories
six
(67%)
nine
declining
remainder.
5
percentage
points
higher
among
female
(33·8%
[29·9–37·7])
than
male
(28·7%
[25·0–32·6])
individuals.
increased
people
aged
60
years
older
all
regions
both
sexes,
but
age
patterns
differed
those
younger
years.
If
continue,
between
2010
will
be
met
(posterior
probability
<0·01);
however,
two
Oceania
sub-Saharan
Africa,
were
on
track
considerable
probabilities
0·70–0·74).InterpretationConcerted
multi-sectoral
efforts
reduce
levels
are
needed
target.
Physical
promotion
should
exacerbate
sex,
geographical
inequalities.FundingMinistry
Public
Health,
Qatar,
World
Health
Organization.TranslationsFor
Spanish
Portuguese
translations
abstract
see
Supplementary
Materials
section.
The Lancet,
Journal Year:
2024,
Volume and Issue:
404(10467), P. 2077 - 2093
Published: Nov. 1, 2024
Diabetes
can
be
detected
at
the
primary
health-care
level,
and
effective
treatments
lower
risk
of
complications.
There
are
insufficient
data
on
coverage
treatment
for
diabetes
how
it
has
changed.
We
estimated
trends
from
1990
to
2022
in
prevalence
200
countries
territories.
JAMA,
Journal Year:
2024,
Volume and Issue:
332(7), P. 571 - 571
Published: Aug. 20, 2024
Obesity
affects
approximately
19%
of
women
and
14%
men
worldwide
is
associated
with
increased
morbidity.
Antiobesity
medications
(AOMs)
modify
biological
processes
that
affect
appetite
significantly
improve
outcomes,
such
as
type
2
diabetes,
hypertension,
dyslipidemia.
European Heart Journal,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 30, 2024
The
global
prevalence
of
obesity
has
more
than
doubled
over
the
past
four
decades,
currently
affecting
a
billion
individuals.
Beyond
its
recognition
as
high-risk
condition
that
is
causally
linked
to
many
chronic
illnesses,
been
declared
disease
per
se
results
in
impaired
quality
life
and
reduced
expectancy.
Notably,
two-thirds
obesity-related
excess
mortality
attributable
cardiovascular
disease.
Despite
increasingly
appreciated
link
between
broad
range
manifestations
including
atherosclerotic
disease,
heart
failure,
thromboembolic
arrhythmias,
sudden
cardiac
death,
underrecognized
sub-optimally
addressed
compared
with
other
modifiable
risk
factors.
In
view
major
repercussions
epidemic
on
public
health,
attention
focused
population-based
personalized
approaches
prevent
weight
gain
maintain
healthy
body
from
early
childhood
throughout
adult
life,
well
comprehensive
loss
interventions
for
persons
established
obesity.
This
clinical
consensus
statement
by
European
Society
Cardiology
discusses
current
evidence
epidemiology
aetiology
obesity;
interplay
obesity,
factors
conditions;
management
patients
strategies
lifestyle
changes,
interventional
procedures,
anti-obesity
medications
particular
focus
their
impact
cardiometabolic
outcomes.
document
aims
raise
awareness
factor
provide
guidance
implementing
evidence-based
practices
prevention
optimal
within
context
primary
secondary
prevention.
New England Journal of Medicine,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 13, 2024
BackgroundObesity
is
chronic
disease
and
causal
precursor
to
myriad
other
conditions,
including
type
2
diabetes.
In
an
earlier
analysis
of
the
SURMOUNT-1
trial,
tirzepatide
was
shown
provide
substantial
sustained
reductions
in
body
weight
persons
with
obesity
over
a
72-week
period.
Here,
we
report
3-year
safety
outcomes
its
efficacy
reducing
delaying
progression
diabetes
both
prediabetes.MethodsWe
performed
phase
3,
double-blind,
randomized,
controlled
trial
which
2539
participants
obesity,
whom
1032
also
had
prediabetes,
were
assigned
1:1:1:1
ratio
receive
at
once-weekly
dose
5
mg,
10
or
15
mg
placebo.
The
current
involved
who
received
their
placebo
for
total
176
weeks,
followed
by
17-week
off-treatment
three
key
secondary
end
points,
I
error,
percent
change
from
baseline
week
onset
during
176-week
193-week
periods.ResultsAt
mean
among
−12.3%
5-mg
dose,
−18.7%
10-mg
−19.7%
15-mg
as
compared
−1.3%
those
(P<0.001
all
comparisons
placebo).
Fewer
diagnosis
groups
than
group
(1.3%
vs.
13.3%;
hazard
ratio,
0.07;
95%
confidence
interval
[CI],
0.0
0.1;
P<0.001).
After
17
weeks
off
treatment
placebo,
2.4%
13.7%
(hazard
0.12;
CI,
0.1
0.2;
Other
coronavirus
2019,
most
common
adverse
events
gastrointestinal,
mild
moderate
severity
occurred
primarily
dose-escalation
period
first
20
trial.
No
new
signals
identified.ConclusionsThree
years
prediabetes
resulted
reduction
markedly
lower
risk
that
(Funded
Eli
Lilly;
ClinicalTrials.gov
number,
NCT04184622.)
Clinical and Molecular Hepatology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 19, 2024
As
the
rates
of
obesity
and
type
2
diabetes
(T2D)
continue
to
increase
globally,
so
does
prevalence
metabolic
dysfunction
associated
steatotic
liver
disease
(MASLD).
Currently,
38%
all
adults
7-14%
children
adolescents
have
MASLD.
By
2040,
MASLD
rate
for
is
projected
over
55%.
Although
many
with
will
not
develop
progressive
disease,
given
vast
number
patients
MASLD,
it
has
now
become
top
indication
transplant
in
United
States
those
hepatocellular
carcinoma
(HCC)
women.
However,
most
common
cause
mortality
among
remains
death
cardiovascular
diseases.
In
addition
outcomes
(cirrhosis
HCC),
increased
risk
developing
de-novo
T2D,
chronic
kidney
sarcopenia
extrahepatic
cancers.
Furthermore,
decreased
health
related
quality
life,
work
productivity,
fatigue
healthcare
resource
utilization
substantial
economic
burden.
Similar
other
lifestyle
interventions
heathy
diet
physical
activity
remain
cornerstone
managing
these
patients.
a
T2D
drugs
are
available
treat
co-morbid
Resmetirom
only
MASH-targeted
medication
that
was
recently
approved
by
Federal
Drug
Administration
use
stage
2-3
fibrosis.
The
following
review
provides
an
overview
epidemiology,
its
factors
demonstrates
without
further
global
initiatives,
may
increase.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(13), P. 7342 - 7342
Published: July 4, 2024
Obesity,
primarily
characterized
by
excessive
fat
accumulation,
is
a
multifactorial
chronic
disease
with
an
increasing
global
prevalence.
Despite
the
well-documented
epidemiology
and
significant
advances
in
understanding
its
pathophysiology
clinical
implications,
impact
of
sex
typically
overlooked
obesity
research.
Worldwide,
women
have
higher
likelihood
to
become
obese
compared
men.
Although
are
offered
weight
loss
interventions
more
often
at
earlier
stages
than
men,
they
vulnerable
psychopathology.
Men,
on
other
hand,
less
likely
pursue
intervention
susceptible
metabolic
implications
obesity.
In
this
narrative
review,
we
comprehensively
explored
sex-
gender-specific
differences
development
obesity,
focusing
variety
biological
variables,
such
as
body
composition,
distribution
energy
partitioning,
steroid
hormones
gut
microbiota
diversity,
chromosomal
genetic
behavioural
sociocultural
variables
influencing
men
women.
Sex
obesity-related
comorbidities
varying
effectiveness
different
also
extensively
discussed.
ACSMʼs Health & Fitness Journal,
Journal Year:
2024,
Volume and Issue:
28(6), P. 11 - 25
Published: Oct. 30, 2024
Apply
It!
•
Identify
predictions
for
the
top
20
fitness
trends
in
United
States
and
across
globe
2025.
Utilize
data
informed
decision
making
to
promote
physical
activity
commercial,
clinical,
corporate,
community
sectors.
Evaluate
trend
themes
regions
support
consumer
health
fitness.
European Journal of Preventive Cardiology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 30, 2024
The
global
prevalence
of
obesity
has
more
than
doubled
over
the
past
four
decades,
currently
affecting
a
billion
individuals.
Beyond
its
recognition
as
high-risk
condition
that
is
causally
linked
to
many
chronic
illnesses,
been
declared
disease
per
se
results
in
impaired
quality
life
and
reduced
expectancy.
Notably,
two-thirds
obesity-related
excess
mortality
attributable
cardiovascular
disease.
Despite
increasingly
appreciated
link
between
broad
range
manifestations
including
atherosclerotic
disease,
heart
failure,
thromboembolic
arrhythmias,
sudden
cardiac
death,
underrecognized
sub-optimally
addressed
compared
with
other
modifiable
risk
factors.
In
view
major
repercussions
epidemic
on
public
health,
attention
focused
population-based
personalized
approaches
prevent
weight
gain
maintain
healthy
body
from
early
childhood
throughout
adult
life,
well
comprehensive
loss
interventions
for
persons
established
obesity.
This
clinical
consensus
statement
by
European
Society
Cardiology
discusses
current
evidence
epidemiology
aetiology
obesity;
interplay
obesity,
factors
conditions;
management
patients
strategies
lifestyle
changes,
interventional
procedures,
anti-obesity
medications
particular
focus
their
impact
cardiometabolic
outcomes.
document
aims
raise
awareness
factor
provide
guidance
implementing
evidence-based
practices
prevention
optimal
within
context
primary
secondary
prevention.
